Third‐generation EGFR inhibitor HS ‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR ‐mutant non‐small cell lung cancer cells
Author:
Affiliation:
1. School of Life Sciences, Shanghai University Shanghai China
2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai China
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13902
Reference24 articles.
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
2. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
3. Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
4. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
5. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI);Advances in Oncology;2024-05
2. Antineoplastic indole-containing compounds with potential VEGFR inhibitory properties;RSC Advances;2024
3. Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants;Clinical Pharmacology in Drug Development;2023-03-03
4. Efficacy of PP121 in primary and metastatic non‑small cell lung cancers;Biomedical Reports;2023-03-01
5. Evaluating Social and Spatial Equity in Public Transport: A Case Study;Transportation Letters;2022-12-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3